14.42
-0.01 (-0.07%)
| Penutupan Terdahulu | 14.43 |
| Buka | 14.41 |
| Jumlah Dagangan | 2,579,252 |
| Purata Dagangan (3B) | 6,969,405 |
| Modal Pasaran | 4,527,889,920 |
| Harga / Pendapatan (P/E Ke hadapan) | 30.49 |
| Harga / Jualan (P/S) | 6.99 |
| Harga / Buku (P/B) | 16.46 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Keuntungan | -5.41% |
| Margin Operasi (TTM) | -6.35% |
| EPS Cair (TTM) | -0.090 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 13.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 229.11% |
| Nisbah Semasa (MRQ) | 3.34 |
| Aliran Tunai Operasi (OCF TTM) | 3.56 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 29.27 M |
| Pulangan Atas Aset (ROA TTM) | 3.95% |
| Pulangan Atas Ekuiti (ROE TTM) | -18.12% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Amicus Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.13 |
|
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.72% |
| % Dimiliki oleh Institusi | 103.25% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Hbk Investments L P | 31 Dec 2025 | 15,250,000 |
| Soleus Capital Management, L.P. | 31 Dec 2025 | 5,207,284 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 14.50 (Jefferies, 0.56%) | Pegang |
| 14.50 (Leerink Partners, 0.56%) | Pegang | |
| Median | 14.50 (0.56%) | |
| Purata | 14.50 (0.56%) | |
| Jumlah | 2 Pegang | |
| Harga Purata @ Panggilan | 14.26 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Jefferies | 22 Jan 2026 | 14.50 (0.55%) | Pegang | 14.27 |
| Leerink Partners | 29 Dec 2025 | 14.50 (0.55%) | Pegang | 14.25 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |